Elimination of Hepatitis C in Turkey
<p id="p1">This manuscript examines the epidemiological patterns, transmission routes, and genotypic distribution of hepatitis C virus (HCV) in Türkiye, highlighting national progress toward elimination targets set by the World Health Organization (WHO). The main objective is to evaluate the ef...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2025
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/89839 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | <p id="p1">This manuscript examines the epidemiological patterns, transmission routes, and genotypic distribution of hepatitis C virus (HCV) in Türkiye, highlighting national progress toward elimination targets set by the World Health Organization (WHO). The main objective is to evaluate the effectiveness of national screening, diagnostic, and treatment strategies, with a focus on the scale-up of direct-acting antiviral (DAA) therapies and their associated cost-effectiveness. Drawing on recent multicenter and population-based studies, the paper outlines the shifting prevalence of HCV genotypes, particularly among high-risk populations such as people who inject drugs (PWID), prisoners, and individuals undergoing hemodialysis. The analysis demonstrates that genotype 1b remains predominant, though genotype diversity is increasing due to migration and changing transmission dynamics. Findings reveal that despite improved availability of DAA treatments and health policy initiatives like the 2018–2023 National Viral Hepatitis Program, gaps persist in diagnostic follow-up and referral. The manuscript emphasizes the dual approach of micro- and macro-elimination, advocating for integrated care models, increased physician engagement, and enhanced awareness efforts. Projections suggest that achieving WHO goals is feasible in Türkiye if testing and treatment rates significantly improve. Ultimately, this study underscores the necessity of sustained political commitment, intersectoral collaboration, and targeted public-health interventions to reduce HCV-related morbidity and mortality by 2030.</p> |
|---|---|
| ISBN: | 978-1-80632-102-5 |
| DOI: | 10.5772/intechopen.115657 |